Document is current
Any future updates will be listed below
-
Authors
Heikkinen, Sami https://orcid.org/0000-0002-6083-2402
Julkunen, Valtteri
Martiskainen, Henna
Takalo, Mari
Solje, Eino https://orcid.org/0000-0001-9940-9524
Leinonen, Ville
Haapasalo, Annakaisa https://orcid.org/0000-0003-0959-2957
Lipponen, Anssi
Hiltunen, Mikko https://orcid.org/0000-0003-3566-4096
- License Information
-
More Information
Article History
Received: 18 January 2026
Revised: 11 May 2026
Accepted: 3 June 2026
First Online: 12 June 2026
Competing interests
: All authors have approved the final version of the manuscript and give their consent for publication. E. Solje has served on the advisory board of Novartis, Eisai, Eli Lilly and Roche, served as a consultant for Novo Nordisk, Eli Lilly, Eisai, BioArctic and Roche and received honoraria from lectures from Lundbeck, BioaArctic, TEVA, Eli Lilly and Roche and received travel support from Eli Lilly and Merck and received research funding from Roche and Eli Lilly. E Solje is editor of Alzheimer’s Research & Therapy and associate editor of Journal of Alzheimer’s disease. The other authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
